Aptinyx Inc (APTX)

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aptinyx Inc (APTX)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aptinyx Inc.(“Aptinyx” or the “Company”) (NASDAQ: APTX). The investigation concerns whether Aptinyx and certain of its officers and/or directors have violated federal securities laws.


In June 2018, Aptinyx completed its initial public offering (“IPO”) of common stock, selling over 7.3 million shares of stock priced at $16.00 per share, for gross proceeds of over $117 million.  Then, on January 16, 2019, Aptinyx announced top-line results from a Phase 2 clinical study of NYX-2925, the Company’s proposed treatment of painful diabetic peripheral neuropathy, and disclosed that “NYX-2925 did not demonstrate statistically significant separation from placebo on the primary endpoint, change in subjects’ average daily pain scores on the Numerical Rating Scale (NRS) during the final treatment week compared to baseline.”  On this news, Aptinyx’s stock price fell $11.85 per share, or 66.46%, to close at $5.98 per share on January 16, 2019.  Since the IPO, Aptinyx’s stock price has closed as low as $2.84 per share, representing a decline of more than 82% from the offering price.


If you are aware of any facts relating to this investigation, or purchased Aptinyx shares, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 


Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2019 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.